Wayfinder Biosciences

Wayfinder develops therapeutics that neutralize the toxic effects of disease genes by turning them off at the source, their mRNA. Most diseases are driven by disregulated proteins, and traditional therapies try to block these proteins directly. However, despite decades of research, many key targets remain untreatable.

Operating in biopharma based in Seattle, Washington, US, Wayfinder Biosciences was founded in 2021.

Profile

Wayfinder is using computational design to program RNA logic themselves, specifically controlling how cells respond on demand using the molecules they choose. Wayfinder is unlocking the future of biomanufacturing with nano-scale sensors that light up to discover cells thousands of times faster than biotech’s billion-dollar companies. What comes next is the future of everything else, from smart mRNA vaccines and smart cell factories to smart CRISPR.

Within the biopharma space, the company focuses on its core offering rather than a broad product line.

The business is associated with Seattle, Washington, US.

Directory data places it at the SOSV portfolio company stage.

The company reports a headcount in the 2-10 range.

Website: wayfinderbio.com